

BUILDING ONTO THE CLINICAL EXPERIENCE OF TRASTUZUMAB WITH PFIZER



For early or metastatic HER2+ breast cancer patients, there is an additional option for trastuzumab treatment¹

SIMILAR PRODUCT PROFILE	TRAZIMERA has efficacy and safety profiles similar to those of Herceptin® (trastuzumab)²
BACKED BY PFIZER	TRAZIMERA is part of a large biosimilar portfolio from Pfizer^{1,3-5}
POTENTIAL COST SAVINGS	BIOSIMILARS have the potential to create savings and efficiencies for the healthcare system⁶

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions

SmPC available [here](#).

www.pfizer.com

Herceptin is a registered trademark of Genentech, Inc.

References: 1. TRAZIMERA Summary of Product Characteristics. Pfizer Inc., New York, NY. 2. Pegram M, Tan-Chiu E, Freyman A, et al. A randomised, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer. Poster 238PD presented at: European Society for Medical Oncology (ESMO) Congress; September 8-12, 2017; Madrid, Spain. 3. European Medicines Agency. Retacrit. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000872/WC500054372.pdf. Updated July 2011. Accessed September 9, 2020. 4. European Medicines Agency. Nivestim. <https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim>. Updated December 4, 2018. Accessed September 9, 2020. 5. European Medicines Agency. Inflectra. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002778/WC500151491.pdf. Updated September 2013. Accessed September 9, 2020. 6. IMS Institute for Healthcare Informatics. *Delivering on the Potential of Biosimilar Medicines: The Role of Functioning Competitive Markets*. Parsippany, NJ: IMS; March 2016.